B. Crestani (Paris, France), R. Borie (Paris, France)
LSC - 2020 - The respiratory microbiome and metabolome in chronic hypersensitivity pneumonitis
R. Invernizzi (London, United Kingdom)
|     |
Methotrexate and risk of Lung disease in Rheumatoid Arthritis: A nationwide population-based cohort study from Denmark
S. Burhan Shaker (Copenhagen, Denmark), E. Ibfelt (Copenhagen, Denmark), R. Jacobsen (Copenhagen, Denmark), T. Kopp (Copenhagen, Denmark), R. Cordtz (Aalborg, Denmark), A. Jakobsen (Copenhagen, Denmark), N. Seersholm (Copenhagen, Denmark), L. Dreyer (Aalborg, Denmark)
| |
Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease
S. Scharm (Hannover, Germany), S. Dettmer (Hannover, Germany), J. Vogel-Claussen (Hannover, Germany), A. Prasse (Hannover, Germany), L. Knudsen (Hannover, Germany), F. Wacker (Hannover, Germany), J. Fuge (Hannover, Germany), H. Shin (Hannover, Germany)
| |
Does nintedanib have the same effect on FVC decline in patients with progressive fibrosing ILDs treated with DMARDs or glucocorticoids?
N. Chaudhuri (Wythenshawe, Manchester, United Kingdom), V. Cottin (Lyon, France), S. Cerri (Modena, Italy), M. Kreuter (Heidelberg, Germany), M. Otaola (Buenos Aires, Argentina), D. Castillo Villegas (Barcelona, Spain), C. Glazer (Dallas, Texas, United States of America), H. Müller (Ingelheim am Rhein, Germany), C. Coeck (Brussels, Belgium), M. Quaresma (Ingelheim am Rhein, Germany), T. Maher (London, United Kingdom)
| |
Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial
C. Valenzuela (Madrid, Spain), T. Maher (London, United Kingdom), F. Bonella (Essen, Germany), A. Pesci (Monza, Italy), S. Jouneau (F-35000 Rennes, France), N. Patel (New York, NY, United States of America), E. Fernández Pérez (Denver, CO, United States of America), R. Goeldner (Biberach, Germany), S. Stowasser (Ingelheim am Rhein, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), M. Quaresma (Ingelheim am Rhein, Germany), V. Cottin (Lyon, France)
| |
Effects of nintedanib on progression of ILD in patients with fibrosing ILDs and a progressive phenotype: further analyses of the INBUILD trial
K. Flaherty (Ann Arbor, MI, United States of America), A. Wells (London, United Kingdom), V. Cottin (Lyon, France), A. Devaraj (London, United Kingdom), Y. Inoue (Sakai City, Osaka, Japan), L. Richeldi (Rome, Italy), S. Walsh (London, United Kingdom), M. Kolb (Hamilton, Ontario, Canada), D. Koschel (Coswig, Germany), T. Moua (Rochester, MN, United States of America), S. Stowasser (Ingelheim am Rhein, Germany), R. Goeldner (Biberach, Germany), R. Schlenker-Herceg (Ridgefield, CT, United States of America), K. Brown (Denver, CO, United States of America)
| |